Clinical factors associated with inappropriate prescription of statins

被引:1
作者
Lahoz, Carlos
Vicente, Ignacio
Criado, Antonio
Laguna, Fernando
Torrecilla, Esther
Maria Mostaza, Jose
机构
[1] Hosp Carlos III, Med Interna Serv, Unidad Arteriosclerosis, Madrid 28029, Spain
[2] Hosp Mostoles, Serv Cardiol, Madrid, Spain
来源
MEDICINA CLINICA | 2007年 / 129卷 / 03期
关键词
statins; prescription; primary prevention; diabetes; secondary prevention;
D O I
10.1157/13107367
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: The aim of this study was to determine the percentage of subjects receiving statin treatment that was inappropriate and to evaluate the associated clinical factors. PATIENTS AND METHOD: A cross-sectional multi-centred study conducted across the Autonomous Regions of Spain. The appropriateness of prescription was based on the guidelines of the. National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) and the European Guidelines on Cardiovascular Disease Prevention. RESULTS: Of the 1,817 patients studied, 52.9% were male, the overall mean age was 59.4 years, 36% had cardiovascular disease and 32.7% had diabetes. In 90.8% of the population the prescription was correct according to at least one of the two guides being used, with a low concordance between them (kappa = 0.279). Almost 100% of subjects with cardiovascular disease or diabetes had an appropriate prescription. In primary prevention, 82.7% had an appropriate prescription according to at least one of the two guides used, but this percentage decreased to 20.7% when based on the European Guidelines. In multivariate analysis, there was agreement with both guides. The inappropriate prescription was directly, and significantly, associated with primary prevention and female gender, while being inversely related to age, smoking habit and LDL-cholesterol concentration. CONCLUSIONS: Most of the patients receiving statin treatment have an appropriate prescription, but the percentage of inappropriate prescription increases significantly in patients in primary prevention following European Guidelines.
引用
收藏
页码:86 / 90
页数:5
相关论文
共 19 条
[1]   Use and monitoring of "statin" lipid-lowering drugs compared with guidelines [J].
Abookire, SA ;
Karson, AS ;
Fiskio, J ;
Bates, DW .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (01) :53-58
[2]  
Álvarez Cosmea Artemio, 2005, Rev. Esp. Salud Publica, V79, P465, DOI [10.1590/S1135-57272005000400004, 10.1590/s1135-57272005000400004]
[3]  
Artalejo FR, 1999, MED CLIN-BARCELONA, V112, P459
[4]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[5]   The cost of inadequate prescriptions for hypolipidaemic drugs [J].
Ballesteros, LC ;
San Martín, MIF ;
Cuesta, TS ;
Mayor, EE ;
Bilbao, CL .
PHARMACOECONOMICS, 2001, 19 (05) :513-522
[6]   International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis [J].
Bhatt, DL ;
Steg, PG ;
Ohman, EM ;
Hirsch, AT ;
Ikeda, Y ;
Mas, JL ;
Goto, S ;
Liau, CS ;
Richard, AJ ;
Röther, J ;
Wilson, PWF ;
Andersen-Dalheim, H ;
Anderson, P ;
Anell, B ;
Arber, S ;
Armstrong, K ;
Arnot, D ;
Baldam, A ;
Barratt, I ;
Barresi, S ;
Beder, J ;
Benson, M ;
Bergman, F ;
Best, J ;
Bhasim, R ;
Bovell, G ;
Bowman, N ;
Brkic, M ;
Bromberger, D ;
Brown, D ;
Brown, J ;
Brownstein, M ;
Bruce, A ;
Buonopane, J ;
Burns, S ;
Butler, A ;
Byrne, D ;
Carson, J ;
Cassimatis, P ;
Chaffey, G ;
Chambers, D ;
Chan, WJ ;
Chan, B ;
Cheatham, J ;
Chen, R ;
Cheong, B ;
Cheung, C ;
Chin, J ;
Chiu, A ;
Choo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02) :180-189
[7]  
Brotons Carlos, 2004, Rev. Esp. Salud Publica, V78, P435
[8]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[9]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3